Ann: Orthocell announces successful capital raising, page-23

You have a stock that was predominantly retail or angel investor held. Past CR have been open to retail. This one was institutional only. I am surprised the stock is at the discounted CR price - unless the CR was a lot of 'sophisticated' investors buying at the $0.40 price and selling at anything above for a quick relatively riskless profit. This firm has survived for years on a lot less cash. My one criticism is a failure to monetise its ATI procedure in Australia via full paying customers (and seriously afflicted people in Australia who've exhausted [ultimately limited] surgical and traditional methods will think nothing of dropping $5K+ on one of the few regenerative options out there for tendons) in the last few years whilst pursuing the Medicare avenue. It looks clear (IMO) the company is finally on the verge of monetising that and a second great product in CelGro.